06/24/22 7:31 AMNasdaq : REGN, NTLA clinical trialIntellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single DoseSerum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg cohortsPharmacokinetic modeling and simulation indicated that an 80 mg fixed dose provides similar exposure to the 1.0 mg/kg dose, whereRHEA-AIneutral
06/07/22 4:44 PMNasdaq : SNY, REGN fda approvalFDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic DermatitisChildren treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, experienced significantly improved overall disease severity and significantly reduced itch compared to TCS alone at week 16 in a Phase 3 trialLong-term safety data from a 52-week open-label extension trial inRHEA-AIneutral
06/02/22 7:30 AMNasdaq : REGN Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of CancerRegeneron will secure global rights to Libtayo from Sanofi in exchange for upfront payment of $900 million, plus royalties and potential future milestone payments18 different investigational treatment combinations with Libtayo currently being evaluated in 22 clinical trialsRegeneron will host anRHEA-AIpositive
05/31/22 8:31 AMNasdaq : REGN acquisitionRegeneron Completes Acquisition of Checkmate PharmaceuticalsRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully acquired CheckmateRHEA-AIpositive
05/31/22 12:59 AMNasdaq : REGN, SNY FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo NodularisDupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approvedRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug AdministrationRHEA-AIneutral
05/21/22 7:00 AMNasdaq : REGN clinical trialEvkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High CholesterolChildren already on other lipid-lowering therapies entered the trial with dangerously high LDL-C (264 mg/dL on average), and 79% saw their LDL-C reduced by at least half at 24 weeksFDA submission planned by end of 2022Regeneron Pharmaceuticals,RHEA-AIneutral
05/20/22 3:15 PMNasdaq : REGN, SNY fda approvalFDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic EsophagitisDupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA's Priority Review action dateDupixent 300 mg weekly significantly improved signs andRHEA-AIpositive
05/17/22 7:00 AMNasdaq : REGN Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics EntrepreneurVyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced $29.5M in new funding led by Mr. Harry Stine of Stine Seed Farms, Inc. with participation from existingRHEA-AIneutral
05/13/22 1:13 PMNasdaq : REGN High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering FairRegeneron Pharmaceuticals, Inc. and Society for Science (theRHEA-AIpositive
05/13/22 11:52 AMNasdaq : REGN High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering FairRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society forRHEA-AIpositive